What molecular mechanisms determine whether reactive astrocytes adopt neurotoxic A1 vs neuroprotective A2 phenotypes?
PARTIALLY ADDRESSED
The abstract describes astrocyte phenotypic heterogeneity (A1/A2) but doesn't explain the mechanistic switches governing this critical fate decision. Understanding these mechanisms is essential for therapeutic targeting of beneficial vs harmful astrocyte responses.
Gap type: unexplained_observation
Source paper: Contribution of astrocytes to neuropathology of neurodegenerative diseases. (2021, Brain research, PMID:33516810)
Landscape Summary:
What molecular mechanisms determine whether reactive astrocytes adopt neurotoxic A1 vs neuroprotective A2 phenotypes? is a 0.89 priority gap in neuroinflammation.
It has 0 linked hypotheses with average composite score 0.000.
Status: partially_addressed.
Key Unanswered Questions
What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?
Key Researchers
Colonna, Sevlever, et al. (TREM2 biology)
Clinical Trials
What molecular mechanisms determine whether reactive astrocytes adopt neurotoxic A1 vs neuroprotective A2 phenotypes? — INVOKE-2 (completed)